Tenecteplase differs from alteplase pharmacologically in which set of properties?

• A Shorter half-life, lower fibrin specificity, given as infusion
• B Identical half-life but requires antistreptococcal antibody screening
• C Longer half-life, higher fibrin specificity, greater resistance to PAI-1, single bolus administration ✓
• D Direct plasmin activation independent of plasminogen binding

Explanation

Tenecteplase is a genetically engineered alteplase variant with amino acid substitutions that increase fibrin binding and specificity, confer resistance to plasminogen activator inhibitor-1, and extend the half-life to roughly 20 minutes versus about 5 minutes for alteplase. These changes permit weight-adjusted single bolus dosing, unlike the 90 minute alteplase infusion. It remains a plasminogen activator and shares alteplase's non-antigenic nature.

Reference: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.